120
Participants
Start Date
January 31, 2004
Primary Completion Date
May 31, 2010
Study Completion Date
May 31, 2010
Neridronate
"Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication Osteogenesis Imperfecta."
Centro della Microcitemia e delle Anemie Congenite - Ematologia E.O. Ospedali Galliera, Genova
SC Geriatria E.O. Ospedali Galliera, Genova
Centro Anemie Congenite, Ospedale Maggiore Policlinico, IRCCS, University of Milan, Milan
"Divisione di Ematologia, Ospedale Perrino", Brindisi
Dipartimento di Medicina Clinica e Sperimentale, Sezione di Pediatria, Università di Ferrara, Ferrara
"U.O. Ematologia II con Talassemia A.O. V. Cervello", Palermo
"U.O. Pediatria II, A.O. Villa Sofia", Palermo
Centro Microcitemia, A.O. B.M.M., Reggio Calabria
Ospedale Maggiore Policlinico Mangiagalli e Regina Elena
OTHER
"Ospedale Perrino Brindisi"
UNKNOWN
Reggio Calabria
OTHER
Azienda Ospedaliera Villa Sofia
UNKNOWN
Azienda Ospedaliera V. Cervello
OTHER
Università di Ferrara
UNKNOWN
University of Campania Luigi Vanvitelli
OTHER
Ente Ospedaliero Ospedali Galliera
OTHER